Hence, in the present study, we aim to develop a localized, sustained co-delivery strategy of SLP2 shRNA and GO-CET/CPT11 (CPT-11 loaded to GO-CET) by utilizing the biodegradable CPN hydrogel as an injectable hydrogel depot for the treatment of glioblastoma in vitro and in vivo (Figure 1). This evidence concerns the gene STOML2 and glioblastoma.